Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Diane Marie Da Silva, PhD, MS

    AddressNRT 7517
    Health Sciences Campus
    Los Angeles California 90089-9601
    Phone+1 323 442 3868
    vCardDownload vCard

      Collapse Overview 
      Collapse Overview
      Dr. Da Silva's current research interests span multiple areas of study that include applying immune modulation strategies to enhance natural and vaccine-induced immunity against Human papillomavirus, investigating the molecular and cellular determinants in the tumor microenvironment that lead to cervical and ovarian cancer progression and metastasis, and assessing the clinical significance of the cervico-vaginal microbiota in relation to chronic inflammation and cervical precancerous lesion progression.

      Dr. Da Silva has spent the past 15 years studying human papillomavirus (HPV) interactions with host immune cell receptors and immune escape mechanisms used by HPV, and has been involved with development of therapeutic vaccine strategies against HPV-induced cancers. She has broad expertise and skills associated with immunology, oncology and infectious disease research, immunotherapeutics, vaccine immunogenicity and efficacy, pre-clinical vaccine/adjuvant development, small animal syngeneic and xenograft tumor models, clinical translational research, and analysis of immune responses and biomarkers in human samples.

      Dr. Da Silva is the course director for a newly developed undergraduate Introductory course in Modern Oncology and Cancer Biology for the USC Minor in Health Care Studies that started in Spring 2015.

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Woodham AW, Sanna AM, Taylor JR, Skeate JG, Da Silva D, Dekker LV, Kast WM. Annexin A2 antibodies but not inhibitors of the annexin A2 heterotetramer impair productive HIV-1 infection of macrophages in vitro. Virol J. 2016 Nov 18; 13(1):187. PMID: 27863502.
        View in: PubMed
      2. Nicol AF, Brunette LL, Nuovo GJ, Grinsztejn B, Friedman RK, Veloso VG, Cunha CB, Coutinho JR, Vianna-Andrade C, Oliveira NS, Woodham AW, DA Silva DM, Kast WM. Secretory Leukocyte Protease Inhibitor Expression and High-Risk HPV Infection in Anal Lesions of HIV-Positive Patients. J Acquir Immune Defic Syndr. 2016 Sep 01; 73(1):27-33. PMID: 27149102; PMCID: PMC4981526 [Available on 09/01/17].
      3. Woodham AW, Skeate JG, Sanna AM, Taylor JR, Da Silva D, Cannon PM, Kast WM. Human Immunodeficiency Virus Immune Cell Receptors, Coreceptors, and Cofactors: Implications for Prevention and Treatment. AIDS Patient Care STDS. 2016 Jul; 30(7):291-306. PMID: 27410493; PMCID: PMC4948215 [Available on 07/01/17].
      4. Skeate JG, Woodham AW, Einstein MH, Da Silva D, Kast WM. Current therapeutic vaccination and immunotherapy strategies for HPV-related diseases. Hum Vaccin Immunother. 2016 Jun 02; 12(6):1418-29. PMID: 26835746; PMCID: PMC4964648 [Available on 02/02/17].
      5. Da Silva D, Woodham AW, Naylor PH, Egan JE, Berinstein NL, Kast WM. Immunostimulatory Activity of the Cytokine-Based Biologic, IRX-2, on Human Papillomavirus-Exposed Langerhans Cells. J Interferon Cytokine Res. 2016 May; 36(5):291-301. PMID: 26653678; PMCID: PMC4854212.
      6. Da Silva D, Woodham AW, Rijkee LK, Skeate JG, Taylor JR, Koopman ME, Brand HE, Wong MK, McKee GM, Salazar AM, Kast WM. Human papillomavirus-exposed Langerhans cells are activated by stabilized Poly-I:C. Papillomavirus Res. 2015 Dec 01; 1:12-21. PMID: 26665182.
        View in: PubMed
      7. Skeate JG, Porras TB, Woodham AW, Jang JK, Taylor JR, Brand HE, Kelly TJ, Jung JU, Da Silva D, Yuan W, Kast WM. Herpes simplex virus downregulation of secretory leukocyte protease inhibitor enhances human papillomavirus type 16 infection. J Gen Virol. 2016 Feb; 97(2):422-34. PMID: 26555393; PMCID: PMC4804641 [Available on 02/01/17].
      8. Da Silva D, Woodham AW, Skeate JG, Rijkee LK, Taylor JR, Brand HE, Muderspach LI, Roman LD, Yessaian AA, Pham HQ, Matsuo K, Lin YG, McKee GM, Salazar AM, Kast WM. Langerhans cells from women with cervical precancerous lesions become functionally responsive against human papillomavirus after activation with stabilized Poly-I:C. Clin Immunol. 2015 Dec; 161(2):197-208. PMID: 26360252; PMCID: PMC4658296 [Available on 12/01/16].
      9. Bogaert L, Woodham AW, Da Silva D, Martens A, Meyer E, Kast WM. A novel murine model for evaluating bovine papillomavirus prophylactics/therapeutics for equine sarcoid-like tumours. J Gen Virol. 2015 Sep; 96(9):2764-8. PMID: 26044793; PMCID: PMC4635499.
      10. Woodham AW, Taylor JR, Jimenez AI, Skeate JG, Schmidt T, Brand HE, Da Silva D, Kast WM. Small molecule inhibitors of the annexin A2 heterotetramer prevent human papillomavirus type 16 infection. J Antimicrob Chemother. 2015; 70(6):1686-90. PMID: 25712315; PMCID: PMC4447890.
      11. Yan L, Woodham AW, Da Silva D, Kast WM. Functional analysis of HPV-like particle-activated Langerhans cells in vitro. Methods Mol Biol. 2015; 1249:333-50. PMID: 25348318; PMCID: PMC4955845.
      12. Woodham AW, Raff AB, Da Silva D, Kast WM. Molecular analysis of human papillomavirus virus-like particle activated Langerhans cells in vitro. Methods Mol Biol. 2015; 1249:135-49. PMID: 25348303; PMCID: PMC4955848.
      13. Yan L, Da Silva D, Verma B, Gray A, Brand HE, Skeate JG, Porras TB, Kanodia S, Kast WM. Forced LIGHT expression in prostate tumors overcomes Treg mediated immunosuppression and synergizes with a prostate tumor therapeutic vaccine by recruiting effector T lymphocytes. Prostate. 2015 Feb 15; 75(3):280-91. PMID: 25399517; PMCID: PMC4306455.
      14. Woodham AW, Raff AB, Raff LM, Da Silva D, Yan L, Skeate JG, Wong MK, Lin YG, Kast WM. Inhibition of Langerhans cell maturation by human papillomavirus type 16: a novel role for the annexin A2 heterotetramer in immune suppression. J Immunol. 2014 May 15; 192(10):4748-57. PMID: 24719459; PMCID: PMC4019435.
      15. Da Silva D, Movius CA, Raff AB, Brand HE, Skeate JG, Wong MK, Kast WM. Suppression of Langerhans cell activation is conserved amongst human papillomavirus a and ß genotypes, but not a µ genotype. Virology. 2014 Mar; 452-453:279-86. PMID: 24606705; PMCID: PMC3987942.
      16. Raff AB, Woodham AW, Raff LM, Skeate JG, Yan L, Da Silva D, Schelhaas M, Kast WM. The evolving field of human papillomavirus receptor research: a review of binding and entry. J Virol. 2013 Jun; 87(11):6062-72. PMID: 23536685; PMCID: PMC3648114.
      17. Woodham AW, Da Silva D, Skeate JG, Raff AB, Ambroso MR, Brand HE, Isas JM, Langen R, Kast WM. The S100A10 subunit of the annexin A2 heterotetramer facilitates L2-mediated human papillomavirus infection. PLoS One. 2012; 7(8):e43519. PMID: 22927980; PMCID: PMC3425544.
      18. Kanodia S, Da Silva D, Karamanukyan T, Bogaert L, Fu YX, Kast WM. Expression of LIGHT/TNFSF14 combined with vaccination against human papillomavirus Type 16 E7 induces significant tumor regression. Cancer Res. 2010 May 15; 70(10):3955-64. PMID: 20460520; PMCID: PMC2873073.
      19. Clark JI, Moon J, Hutchins LF, Sosman JA, Kast WM, Da Silva D, Liu PY, Thompson JA, Flaherty LE, Sondak VK. Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508. Cancer. 2010 Jan 15; 116(2):424-31. PMID: 19918923; PMCID: PMC2811758.
      20. Fahey LM, Raff AB, Da Silva D, Kast WM. A major role for the minor capsid protein of human papillomavirus type 16 in immune escape. J Immunol. 2009 Nov 15; 183(10):6151-6. PMID: 19864613.
        View in: PubMed
      21. Smith KA, Meisenburg BL, Tam VL, Pagarigan RR, Wong R, Joea DK, Lantzy L, Carrillo MA, Gross TM, Malyankar UM, Chiang CS, Da Silva D, Kündig TM, Kast WM, Qiu Z, Bot A. Lymph node-targeted immunotherapy mediates potent immunity resulting in regression of isolated or metastatic human papillomavirus-transformed tumors. Clin Cancer Res. 2009 Oct 01; 15(19):6167-76. PMID: 19789304; PMCID: PMC2756704.
      22. Fahey LM, Raff AB, Da Silva D, Kast WM. Reversal of human papillomavirus-specific T cell immune suppression through TLR agonist treatment of Langerhans cells exposed to human papillomavirus type 16. J Immunol. 2009 Mar 01; 182(5):2919-28. PMID: 19234187; PMCID: PMC2745289.
      23. Chiriva-Internati M, Cobos E, Da Silva D, Kast WM. Sperm fibrous sheath proteins: a potential new class of target antigens for use in human therapeutic cancer vaccines. Cancer Immun. 2008 Apr 24; 8:8. PMID: 18433090; PMCID: PMC2935778.
      24. Kanodia S, Da Silva D, Kast WM. Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions. Int J Cancer. 2008 Jan 15; 122(2):247-59. PMID: 17973257; PMCID: PMC4943456.
      25. Da Silva D, Fausch SC, Verbeek JS, Kast WM. Uptake of human papillomavirus virus-like particles by dendritic cells is mediated by Fcgamma receptors and contributes to acquisition of T cell immunity. J Immunol. 2007 Jun 15; 178(12):7587-97. PMID: 17548594.
        View in: PubMed
      26. Warrino DE, Olson WC, Scarrow MI, D'Ambrosio-Brennan LJ, Guido RS, Da Silva D, Kast WM, Storkus WJ. Human papillomavirus L1L2-E7 virus-like particles partially mature human dendritic cells and elicit E7-specific T-helper responses from patients with cervical intraepithelial neoplasia or cervical cancer in vitro. Hum Immunol. 2005 Jul; 66(7):762-72. PMID: 16112023.
        View in: PubMed
      27. Fausch SC, Fahey LM, Da Silva D, Kast WM. Human papillomavirus can escape immune recognition through Langerhans cell phosphoinositide 3-kinase activation. J Immunol. 2005 Jun 01; 174(11):7172-8. PMID: 15905561.
        View in: PubMed
      28. Fausch SC, Da Silva D, Kast WM. Heterologous papillomavirus virus-like particles and human papillomavirus virus-like particle immune complexes activate human Langerhans cells. Vaccine. 2005 Feb 25; 23(14):1720-9. PMID: 15705478.
        View in: PubMed
      29. Da Silva D, Schiller JT, Kast WM. Heterologous boosting increases immunogenicity of chimeric papillomavirus virus-like particle vaccines. Vaccine. 2003 Jul 04; 21(23):3219-27. PMID: 12804851.
        View in: PubMed
      30. Fausch SC, Da Silva D, Kast WM. Differential uptake and cross-presentation of human papillomavirus virus-like particles by dendritic cells and Langerhans cells. Cancer Res. 2003 Jul 01; 63(13):3478-82. PMID: 12839929.
        View in: PubMed
      31. Eiben GL, da Silva DM, Fausch SC, Le Poole IC, Nishimura MI, Kast WM. Cervical cancer vaccines: recent advances in HPV research. Viral Immunol. 2003; 16(2):111-21. PMID: 12828864.
        View in: PubMed
      32. Fausch SC, Da Silva D, Eiben GL, Le Poole IC, Kast WM. HPV protein/peptide vaccines: from animal models to clinical trials. Front Biosci. 2003 Jan 01; 8:s81-91. PMID: 12456298.
        View in: PubMed
      33. Fausch SC, Da Silva D, Rudolf MP, Kast WM. Human papillomavirus virus-like particles do not activate Langerhans cells: a possible immune escape mechanism used by human papillomaviruses. J Immunol. 2002 Sep 15; 169(6):3242-9. PMID: 12218143.
        View in: PubMed
      34. Wakabayashi MT, Da Silva D, Potkul RK, Kast WM. Comparison of human papillomavirus type 16 L1 chimeric virus-like particles versus L1/L2 chimeric virus-like particles in tumor prevention. Intervirology. 2002; 45(4-6):300-7. PMID: 12566713.
        View in: PubMed
      35. Da Silva D, Pastrana DV, Schiller JT, Kast WM. Effect of preexisting neutralizing antibodies on the anti-tumor immune response induced by chimeric human papillomavirus virus-like particle vaccines. Virology. 2001 Nov 25; 290(2):350-60. PMID: 11883199.
        View in: PubMed
      36. Rudolf MP, Fausch SC, Da Silva D, Kast WM. Human dendritic cells are activated by chimeric human papillomavirus type-16 virus-like particles and induce epitope-specific human T cell responses in vitro. J Immunol. 2001 May 15; 166(10):5917-24. PMID: 11342606.
        View in: PubMed
      37. Da Silva D, Velders MP, Nieland JD, Schiller JT, Nickoloff BJ, Kast WM. Physical interaction of human papillomavirus virus-like particles with immune cells. Int Immunol. 2001 May; 13(5):633-41. PMID: 11312251.
        View in: PubMed
      38. Small LA, Da Silva D, de Visser KE, Velders MP, Fisher SG, Potkul RK, Kast WM. A murine model for the effects of pelvic radiation and cisplatin chemotherapy on human papillomavirus vaccine efficacy. Clin Cancer Res. 2001 Mar; 7(3 Suppl):876s-881s. PMID: 11300486.
        View in: PubMed
      39. Da Silva D, Eiben GL, Fausch SC, Wakabayashi MT, Rudolf MP, Velders MP, Kast WM. Cervical cancer vaccines: emerging concepts and developments. J Cell Physiol. 2001 Feb; 186(2):169-82. PMID: 11169454.
        View in: PubMed
      40. Nieland JD, Da Silva D, Velders MP, de Visser KE, Schiller JT, Müller M, Kast WM. Chimeric papillomavirus virus-like particles induce a murine self-antigen-specific protective and therapeutic antitumor immune response. J Cell Biochem. 1999 May 01; 73(2):145-52. PMID: 10227378.
        View in: PubMed
      41. Da Silva D, Velders MP, Rudolf MP, Schiller JT, Kast WM. Papillomavirus virus-like particles as anticancer vaccines. Curr Opin Mol Ther. 1999 Feb; 1(1):82-8. PMID: 11249689.
        View in: PubMed
      42. Macedo MF, Velders MP, Nieland JD, Rudolf MP, Weijzen S, Da Silva D, Franke A, Holt G, Loviscek K, Carbone M, Kast WM. Cellular immunity and immunotherapy against deoxyribonucleic acid virus-induced tumors. Monaldi Arch Chest Dis. 1998 Apr; 53(2):211-8. PMID: 9689811.
        View in: PubMed